ENTROPY NEURODYNAMICS LIMITED — Director's Dealing 2024

Jun 5, 2024

Appendix 3Y Change of Director's Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX becomes ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Introduced 30/09/01 Amended 01/01/11
Name of entity	Tryptamine Therapeutics Limited
ABN	41 671 790 935

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of director	Jason Carroll
Date of last notice	4 June 2024

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	(1) Direct
	(2) Direct
	(3) Direct
Nature of indirect interest	N/A
(including registered holder)
Date of change	(1) 5 June 2024
No. of securities held prior to change	(1) 33,500,000 - ORDINARY FULLY PAID SHARES
	(2) 20,000,000 - TRYP TRANS OPT @ $0.027 EXP
	3 YEARS REINSTATEMENT 24M ESC
	(3) 27,892,190 - EMPOPT F @ $0.0338 EXP
	30/10/28 24M ESC
Class	(1) ORDINARY FULLY PAID SHARES
	(2) TRYP TRANS OPT @ $0.027 EXP 3 YEARS
	REINSTATEMENT 24M ESC
	(3) EMPOPT F @ $0.0338 EXP 30/10/28 24M ESC
Number acquired	(1) 952,748 - ORDINARY FULLY PAID SHARES
Number disposed	N/A
Value/Consideration	(1) $0.022 PER ORDINARY FULLY PAID SHARES
	(IN TOTAL $20,960.46)

• See chapter 19 for defined terms. 01/01/2011 Appendix 3Y Page 1

Appendix 3Y Change of Director's Interest Notice

	Appendix 3YChange of Director's Interest Notice
No. of securities held after change	(1) 34,452,748 - ORDINARY FULLY PAID SHARES(2) 20,000,000 - TRYP TRANS OPT @ $0.027 EXP3 YEARS REINSTATEMENT 24M ESC(3) 27,892,190 - EMPOPT F @ $0.0338 EXP30/10/28 24M ESC
Nature of change	(1) ON-MARKET ACQUISITION

Part 2 - Change of director's relevant interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder(if issued securities)	N/A
Date of change	N/A
No. and class of securitiesto which interest relatedprior to change	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration	N/A
Interest after change	N/A

Part 3 -[+] Closed period

Part 3 -+Closed period
Were the interests in the securities orcontracts detailed above traded during a+closed period where prior written clearancewas required?	NO
If so, was prior written clearance provided toallow the trade to proceed during this period?	N/A
If prior written clearance was provided, onwhat date was this provided?	N/A

• See chapter 19 for defined terms. 01/01/2011 Appendix 3Y Page 2